M. Weiss

发表

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

J. Vose, C. Flowers, S. O'brien, 2019, The Lancet. Haematology.

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

J. Burke, J. Reeves, B. Cheson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis

M. Inglese, S. Cocozza, A. Lovett-racke, 2020, Multiple sclerosis.

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

J. Burke, J. Reeves, I. Flinn, 2021, Blood advances.

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.

Michael R Savona, Michael S Weiss, I. Flinn, 2018, The Lancet. Oncology.

Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy.

J. Reeves, I. Flinn, B. Cheson, 2020, Blood.

Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.

J. Vose, C. Flowers, S. O'brien, 2019, Blood.

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

J. Burke, J. Vose, J. Gribben, 2017 .

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.

J. Burke, K. Kolibaba, I. Flinn, 2021, The Lancet. Haematology.

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

J. Burke, K. Kolibaba, D. Mahadevan, 2016, British journal of haematology.

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

J. Burke, J. Gribben, K. Kolibaba, 2020, Blood.

UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY

S. Kambhampati, J. Burke, I. Flinn, 2017 .

Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.

J. Burke, K. Kolibaba, I. Flinn, 2017 .

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

J. Friedberg, J. Liesveld, B. Hill, 2020, Blood.

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation

A. Zelenetz, D. Brander, S. Schuster, 2018, Blood.

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

J. Burke, J. Reeves, B. Cheson, 2020 .

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.

H. Hartung, L. Steinman, K. Selmaj, 2022, The New England journal of medicine.

PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION

A. Zelenetz, E. L. Luning Prak, D. Brander, 2019, Hematological Oncology.

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

J. Burke, J. Gribben, K. Kolibaba, 2021, Blood.

A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY

J. Reeves, I. Flinn, B. Cheson, 2019, Hematological Oncology.

Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results

J. Vose, C. Flowers, S. O'brien, 2015 .

Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL

S. Schuster, A. Mato, M. Shadman, 2017 .

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

J. Friedberg, J. Liesveld, B. Hill, 2019, Blood.

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.

I. Flinn, H. Burris, C. Deng, 2018, The Lancet. Oncology.

Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.

J. Burke, K. Kolibaba, J. Reeves, 2019, Journal of Clinical Oncology.